Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Taeang, Arai"'
Autor:
Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L. Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Masanori Atsukawa, Taeang Arai, Korenobu Hayama, Masatoshi Ishigami, Yong Kyun Cho, Eiichi Ogawa, Hyoung Su Kim, Jae‐Jun Shim, Haruki Uojima, Soung Won Jeong, Sang Bong Ahn, Koichi Takaguchi, Tomonori Senoh, Maria Buti, Elena Vargas‐Accarino, Hiroshi Abe, Hirokazu Takahashi, Kaori Inoue, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lun Yeh, Chia‐Yen Dai, Chung‐Feng Huang, Mindie H. Nguyen, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 40, Iss 2, Pp 188-197 (2024)
Abstract Elevated serum gamma‐glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)‐related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside an
Externí odkaz:
https://doaj.org/article/e34d44b81a6e43dbaa69ede33654fff2
Autor:
Hiroki Ono, Masanori Atsukawa, Akihito Tsubota, Taeang Arai, Kenta Suzuki, Tetsuyuki Higashi, Michika Kitamura, Kaori Shioda‐Koyano, Tadamichi Kawano, Yuji Yoshida, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Chisa Kondo, Mototsugu Nagao, Masato Iwabu, Katsuhiko Iwakiri
Publikováno v:
JGH Open, Vol 8, Iss 4, Pp n/a-n/a (2024)
Abstract Background and Aim This study aimed to clarify the efficacy and safety of 48‐week pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) complicated by dyslipidemia. Methods A total of 110
Externí odkaz:
https://doaj.org/article/cd543728d12b41028b02332794275195
Autor:
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Kazuto Tajiri, Toru Ishikawa, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Chikara Ogawa, Satoru Kakizaki, Noritomo Shimada, Atsushi Naganuma, Kazuhito Kawata, Hisashi Kosaka, Hidekatsu Kuroda, Tomomitsu Matono, Yutaka Yata, Hironori Ochi, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada, Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group)
Publikováno v:
Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024)
Abstract Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total o
Externí odkaz:
https://doaj.org/article/db2c34e45940412fa92f5beffa4e949a
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21680-21693 (2023)
Abstract Aim This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods We included 526 patients who received Atez/Bev and 731
Externí odkaz:
https://doaj.org/article/47d83858206f4fedb8133cae3683b6fd
Autor:
Tomomi Okubo, Masanori Atsukawa, Akihito Tsubota, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Taeang Arai, Korenobou Hayama, Norio Itokawa, Chisa Kondo, Katsuhiko Iwakiri
Publikováno v:
PLoS ONE, Vol 19, Iss 3, p e0299313 (2024)
Sarcopenia frequently and progressively occurs in patients with chronic liver disease. This study aimed to clarify the relationship between vitamin D levels and muscle mass loss. A total of 166 patients with chronic liver disease were enrolled in thi
Externí odkaz:
https://doaj.org/article/8b2f624364754828ba1d6816631f9688
Autor:
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 7772-7783 (2023)
Abstract Aim To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). Methods A total of
Externí odkaz:
https://doaj.org/article/a7cf1ac5e21f496d9993c6013e712e6a
Autor:
Masanori Atsukawa, Akihito Tsubota, Yuichi Tamura, Kaori Koyano‐Shioda, Tadamichi Kawano, Tomomi Okubo, Korenobu Hayama, Taeang Arai, Norio Itokawa, Yu Taniguchi, Yudai Tamura, Chisa Kondo, Katsuhiko Iwakiri
Publikováno v:
JGH Open, Vol 7, Iss 8, Pp 588-590 (2023)
Externí odkaz:
https://doaj.org/article/6ceaa10ffcf34fda8136884866119734
Autor:
Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Joji Tani, Masashi Hirooka, Koichi Takaguchi, Masanori Atsukawa, Shinya Fukunishi, Ei Itobayashi, Kunihiko Tsuji, Kazuto Tajiri, Hironori Ochi, Toru Ishikawa, Satoshi Yasuda, Chikara Ogawa, Hidenori Toyoda, Takeshi Hatanaka, Takashi Nishimura, Satoru Kakizaki, Kazuhito Kawata, Noritomo Shimada, Fujimasa Tada, Kazuhiro Nouso, Akemi Tsutsui, Hideko Ohama, Asahiro Morishita, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Hisashi Kosaka, Michitaka Imai, Atsushi Naganuma, Shinichiro Nakamura, Yohei Koizumi, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, the Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6980-6993 (2023)
Abstract Aim Recently, the neo‐Glasgow prognostic score (GPS), a composite biomarker determined by the C‐reactive protein level and albumin–bilirubin grade, was developed to predict outcomes in hepatocellular carcinoma (HCC) patients who underg
Externí odkaz:
https://doaj.org/article/854b9401831c4efbb38c73548460fcc7
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 5293-5303 (2023)
Abstract Aim This study compared the efficacy and safety of atezolizumab and bevacizumab (Atez/Bev) in patients with viral and non‐viral infection in clinical settings. Methods We conducted the retrospective cohort study of 323 BCLC stage B or C he
Externí odkaz:
https://doaj.org/article/3b57a7d4c4ec46a59efffd15ae9cb329
Autor:
Takeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Satoru Kakizaki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4259-4269 (2023)
Abstract Aim This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). Methods
Externí odkaz:
https://doaj.org/article/9eb7fcd9ba1d4a5b923e4e0d9966ea37